ClariTrial — AI Clinical Trial Intelligence

Explore/CAR-T cell therapy hematologic malignancies trials

Status

Phase

1,110 results for “CAR-T cell therapy hematologic malignancies trials”

Page 1 of 74

NCT03795779

UNKNOWN

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Early Phase 1Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes

CLL1-CD33 cCAR T cells

iCell Gene Therapeutics20 participants2 sites · ChinaCompletes Sep 2022

CT.gov Full analysis →

NCT07429461

Recruiting

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Early Phase 1B-Cell Acute Lymphoblastic Leukemia

SYNCAR-100 Injection

Zhejiang University16 participants1 site · ChinaCompletes Dec 2027

CT.gov Full analysis →

NCT03155191

Active

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1Phase 2Lymphoblastic Leukemia, Acute Adult

TBI-1501

Takara Bio Inc.21 participants11 sites · JapanCompletes Mar 2035

CT.gov Full analysis →

NCT05618041

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

N/AAcute Lymphoblastic LeukemiaLymphomaMultiple Myeloma

CAR-T Autologous T cell injection

Hebei Senlang Biotechnology Inc., Ltd.50 participants1 site · ChinaCompletes Sep 2027

CT.gov Full analysis →

NCT05354973

Recruiting

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy

N/APatient Reported Outcome MeasuresCAR T-Cell Therapy

Consilium CareTM

Stiftung Swiss Tumor Institute11 participants1 site · SwitzerlandCompletes Apr 2025

CT.gov Full analysis →

NCT04500431

UNKNOWN

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Phase 1Multiple Myeloma

Targeting CD269 chimeric antigen receptor engineered T cells

Shanghai Tongji Hospital, Tongji University School of Medicine10 participants1 site · ChinaCompletes Jul 2022

CT.gov Full analysis →

NCT06142188

Not Yet Recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

N/ALymphoma, B-CellLarge B-cell LymphomaFollicular Lymphoma

Relmacabtagene Autoleucel

Shanghai Ming Ju Biotechnology Co., Ltd.150 participants2 sites · ChinaCompletes Dec 2038

CT.gov Full analysis →

NCT06993766

Not Yet Recruiting

The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

N/ARelapsed B-ALLCAR T-cellsCD19-directed CAR T-cell Therapy

King Faisal Specialist Hospital & Research Center100 participantsCompletes May 2030

CT.gov Full analysis →

NCT05621096

Active

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Phase 1DLBCL - Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma

Bridging radiation therapyLiso-celPost-infusion radiation

University of Nebraska33 participants1 site · United StatesCompletes Jan 2025

CT.gov Full analysis →

NCT03958656

Completed

Results posted

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Phase 1Myeloma-MultipleMyeloma, Plasma-Cell

CyclophosphamideFludarabineRimiducid+1 more

National Cancer Institute (NCI)13 participants1 site · United StatesCompletes Oct 2020

CT.gov Full analysis →

NCT04436029

Completed

Results posted

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2Multiple Myeloma

Descartes 11

Cartesian Therapeutics5 participants4 sites · United StatesCompletes Feb 2022

CT.gov Full analysis →

NCT06340737

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Phase 1Follicular LymphomaMantle Cell LymphomaHairy Cell Leukemia

CD22CART Infusion

Stanford University148 participants1 site · United StatesCompletes Apr 2031

CT.gov Full analysis →

NCT05995041

Recruiting

Universal CAR-T Cells Targeting AML

Phase 1Acute Myeloid Leukemia

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells

Shenzhen Geno-Immune Medical Institute30 participants1 site · ChinaCompletes Sep 2026

CT.gov Full analysis →

NCT03203369

Terminated

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Phase 1Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

UCART123

Cellectis S.A.1 participants1 site · United StatesCompletes Jun 2019

CT.gov Full analysis →

NCT07072494

Recruiting

CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study

Phase 1Phase 2Acute Lymphoblastic Leukemia

CD19 CAR-T cells injection

Zhujiang Hospital30 participants2 sites · ChinaCompletes Mar 2027

CT.gov Full analysis →

1–15 of 1,110

Explore/CAR-T cell therapy hematologic malignancies trials

Status

Phase

1,110 results for “CAR-T cell therapy hematologic malignancies trials”

Page 1 of 74

NCT03795779

UNKNOWN

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Early Phase 1Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes

CLL1-CD33 cCAR T cells

iCell Gene Therapeutics20 participants2 sites · ChinaCompletes Sep 2022

CT.gov Full analysis →

NCT07429461

Recruiting

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Early Phase 1B-Cell Acute Lymphoblastic Leukemia

SYNCAR-100 Injection

Zhejiang University16 participants1 site · ChinaCompletes Dec 2027

CT.gov Full analysis →

NCT03155191

Active

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1Phase 2Lymphoblastic Leukemia, Acute Adult

TBI-1501

Takara Bio Inc.21 participants11 sites · JapanCompletes Mar 2035

CT.gov Full analysis →

NCT05618041

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

N/AAcute Lymphoblastic LeukemiaLymphomaMultiple Myeloma

CAR-T Autologous T cell injection

Hebei Senlang Biotechnology Inc., Ltd.50 participants1 site · ChinaCompletes Sep 2027

CT.gov Full analysis →

NCT05354973

Recruiting

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy

N/APatient Reported Outcome MeasuresCAR T-Cell Therapy

Consilium CareTM

Stiftung Swiss Tumor Institute11 participants1 site · SwitzerlandCompletes Apr 2025

CT.gov Full analysis →

NCT04500431

UNKNOWN

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Phase 1Multiple Myeloma

Targeting CD269 chimeric antigen receptor engineered T cells

Shanghai Tongji Hospital, Tongji University School of Medicine10 participants1 site · ChinaCompletes Jul 2022

CT.gov Full analysis →

NCT06142188

Not Yet Recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

N/ALymphoma, B-CellLarge B-cell LymphomaFollicular Lymphoma

Relmacabtagene Autoleucel

Shanghai Ming Ju Biotechnology Co., Ltd.150 participants2 sites · ChinaCompletes Dec 2038

CT.gov Full analysis →

NCT06993766

Not Yet Recruiting

The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

N/ARelapsed B-ALLCAR T-cellsCD19-directed CAR T-cell Therapy

King Faisal Specialist Hospital & Research Center100 participantsCompletes May 2030

CT.gov Full analysis →

NCT05621096

Active

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Phase 1DLBCL - Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma

Bridging radiation therapyLiso-celPost-infusion radiation

University of Nebraska33 participants1 site · United StatesCompletes Jan 2025

CT.gov Full analysis →

NCT03958656

Completed

Results posted

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Phase 1Myeloma-MultipleMyeloma, Plasma-Cell

CyclophosphamideFludarabineRimiducid+1 more

National Cancer Institute (NCI)13 participants1 site · United StatesCompletes Oct 2020

CT.gov Full analysis →

NCT04436029

Completed

Results posted

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2Multiple Myeloma

Descartes 11

Cartesian Therapeutics5 participants4 sites · United StatesCompletes Feb 2022

CT.gov Full analysis →

NCT06340737

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Phase 1Follicular LymphomaMantle Cell LymphomaHairy Cell Leukemia

CD22CART Infusion

Stanford University148 participants1 site · United StatesCompletes Apr 2031

CT.gov Full analysis →

NCT05995041

Recruiting

Universal CAR-T Cells Targeting AML

Phase 1Acute Myeloid Leukemia

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells

Shenzhen Geno-Immune Medical Institute30 participants1 site · ChinaCompletes Sep 2026

CT.gov Full analysis →

NCT03203369

Terminated

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Phase 1Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

UCART123

Cellectis S.A.1 participants1 site · United StatesCompletes Jun 2019

CT.gov Full analysis →

NCT07072494

Recruiting

CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study

Phase 1Phase 2Acute Lymphoblastic Leukemia

CD19 CAR-T cells injection

Zhujiang Hospital30 participants2 sites · ChinaCompletes Mar 2027

CT.gov Full analysis →

1–15 of 1,110